Oncogenic gain-of-function mutations in the extracellular domain of ERBB4 that increase ligand-independent receptor activation have been described in melanoma [29], and it will be interesting to determine whether the focal deletions in the ERBB4 extracellular domain in the mouse models might have a similar effect. The gene discussed is ERBB4; the disease is melanoma.